ALMS — ALUMIS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1847367 ·
Last close
$7.16
Market Cap
$926.76M
52W High
$31.35
52W Low
$4.28
ADV30
4,157,855
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,662,000 | — | -107,031,000 | -142,221,000 | 560,618,000 | 63,706,000 | 108,460,000 |
| Mar 2026 | 1,741,000 | — | -98,409,000 | -93,053,000 | 671,588,000 | 63,885,000 | 104,567,000 |
| Dec 2025 | 1,929,000 | — | -96,445,000 | -92,931,000 | 411,940,000 | 89,670,000 | 110,643,000 |
| Sep 2025 | 2,066,000 | — | -115,292,000 | -110,752,000 | 488,014,000 | 65,257,000 | 103,241,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-376,250,000
Investing CF
$-37,237,000
Financing CF
$349,055,000
CapEx
$-1,183,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.05
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-994,929,000
Inventory
—
Receivables
$2,730,000
ST Investments
$459,058,000
EBIT TTM
$-450,685,000
Pretax Income TTM
$-245,976,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,398,000
EBITDA
$-421,448,992
Free Cash Flow
$-208,637,632
Enterprise Value
$722,349,504
Total Cash
$502,292,992
Total Debt
$36,427,000
Shares Out
129,435,239
Trailing EPS
$-4.11
Book Value
$3.52
ROE
-93.6%
ROA
-45.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 24,050,000 | -453,804,000 | -243,325,000 | 411,940,000 | 110,643,000 | 301,297,000 | -369,523,000 |
| Dec 2024 | 0 | -300,754,000 | -294,233,000 | 340,992,000 | 80,888,000 | 260,104,000 | -255,078,000 |
| Dec 2023 | 0 | -158,174,000 | -154,993,000 | 89,612,000 | 428,872,000 | -339,260,000 | -129,975,000 |
| Dec 2022 | 0 | -113,850,000 | -111,930,000 | 108,168,000 | 303,410,000 | -195,242,000 | -107,722,000 |
TTM Snapshot
Revenues TTM
$8,402,000
NetIncome TTM
$-237,415,000
OpCashFlow TTM
—
Assets (Latest)
$671,588,000
Forward EPS
$-2.87
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MLTX | MoonLake Immunotherapeutics | $920.85M | $10.82 | — |
| ANL | Adlai Nortye Group Ltd. | $917.43M | $15.62 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $916.81M | $49.08 | — |
| JBIO | Jade Biosciences, Inc. | $915.17M | $14.39 | — |
| KURA | Kura Oncology, Inc. | $942.98M | $10.60 | — |
News headlines (Yahoo Finance, 1h cache)
Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
2026-10-09 17:11 · Yahoo
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
2026-10-09 08:00 · Yahoo
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population
2026-09-09 01:30 · Yahoo
Alumis to Participate in Upcoming September Investor Conferences
2026-09-04 12:00 · Yahoo
Is Alumis (ALMS) Overvalued After Its 121% One Year Return?
2026-09-03 14:10 · Yahoo
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy
2026-09-03 12:15 · Yahoo
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair?
2026-09-03 11:06 · Yahoo
Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints
2026-09-03 08:17 · Yahoo
Sector Update: Healthcare Stocks Advance Wednesday Afternoon
2026-09-02 17:38 · Yahoo
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says
2026-09-02 15:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.